ADMA Biologics Stock Gains On FDA Approval For Plasma Collection Facility

The FDA has approved ADMA Biologics Inc's ADMA BioCenters plasma collection facility in Maryville, Tennessee.
The plasma collection facility commenced operations and initiated source plasma collection in Q4 of 2020.
With today's approval, the facility is now licensed to collect and introduce into interstate commerce human source plasma for further manufacturing in the U.S.
ADMA has eight plasma collection facilities, including three FDA-approved facilities. Five of those facilities are now open and collecting plasma, and two additional marketing applications are anticipated over the remainder of 2021.
In total, ADMA remains on track to have 10 or more FDA-approved plasma collection facilities by 2024.
Price Action: ADMA shares are up 13.4% at $1.69 during the premarket session on the last check Monday.
Related content: Benzinga's Full FDA Calendar.